e-learning
resources
Barcelona 2013
Tuesday, 10.09.2013
Pulmonary circulation: clinical treatment
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Acute and chronic effects of PDE5-Is on SpO2 in patients with COPD associated pulmonary hypertension
A. Goudie, P. Hopkinson, B. Lipworth, A. Struthers (Dundee, United Kingdom)
Source:
Annual Congress 2013 –Pulmonary circulation: clinical treatment
Session:
Pulmonary circulation: clinical treatment
Session type:
Thematic Poster Session
Number:
4071
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Goudie, P. Hopkinson, B. Lipworth, A. Struthers (Dundee, United Kingdom). Acute and chronic effects of PDE5-Is on SpO2 in patients with COPD associated pulmonary hypertension. Eur Respir J 2013; 42: Suppl. 57, 4071
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
From pulmonary gas exchange to the interpretation of arterial blood gases
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Comparison pulmonary rehabilitation efficiency in COPD patients between with and without pulmonary hypertension
Source: International Congress 2014 – Latest insights in pulmonary rehabilitation
Year: 2014
Impact of exacerbations on pulmonary arterial enlargement in patients with chronic obstructive pulmonary disease
Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment
Year: 2013
Association between arterial stiffness and acute exacerbations in patients with chronic obstructive pulmonary disease
Source: International Congress 2015 – Notable abstracts in exacerbations, mechanisms and biomarkers in COPD
Year: 2015
Co-morbidities and pulmonary arterial hypertension (PAH) in COPD patients
Source: International Congress 2016 – Comorbidities and exacerbations in COPD
Year: 2016
NT-proBNP in assessment of pulmonary hypertension in COPD patients
Source: Annual Congress 2013 –COPD treatment
Year: 2013
Effects of Valsartan on pulmonary hemodynamics in patients with chronic obstructive pulmonary disease (COPD) and secondary pulmonary hypertension
Source: International Congress 2019 – COPD treatment: cardiovascular, oxygen and vaccination studies
Year: 2019
Pulmonary hypertension in COPD
Source: Eur Respir J 2008; 32: 1371-1385
Year: 2008
Effect of pulmonary-specific vasodilator therapy in patients with chronic obstructive pulmonary disease and pulmonary hypertension. A retrospective analysis
Source: International Congress 2014 – Pulmonary hypertension in lung disease
Year: 2014
Influence of bronchodilators on pulmonary hypertension in patients with chronic obstructive pulmonary disease (COPD)
Source: Eur Respir J 2003; 22: Suppl. 45, 427s
Year: 2003
Conclusion: treatment of pulmonary hypertension in COPD patients
Source: Annual Congress 2005 - COPD - pulmonary haemodynamics and gas exchange
Year: 2005
The prevalence and characteristics of pulmonary hypertension in severe COPD
Source: International Congress 2016 – Pulmonary hypertension in lung disease
Year: 2016
Characteristics of pulmonary function of COPD with and without arterial pulmonary hypertension
Source: International Congress 2014 – Comorbidities
Year: 2014
Prediction of chronic renal failure in patients with chronic obstructive pulmonary disease
Source: International Congress 2014 – COPD: points to ponder
Year: 2014
Acute haemodynamic effects of adaptive servoventilation therapy in patients with pulmonary arterial hypertension and patients with chronic thromboembolic pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: management
Year: 2015
Cardiopulmonary exercise test (CPET) may show initial right cardiac dysfunction in patients with moderate-severe chronic obstructive pulmonary disease (COPD)
Source: International Congress 2014 – Best abstracts in physical activity and exercise testing
Year: 2014
Pulmonary hypertension (PH) in chronic obstructive pulmonary disease (COPD): Preliminary data of a longitudinal survey
Source: International Congress 2014 – Clinical presentations
Year: 2014
Systemic vascular function in chronic obstructive pulmonary disease
Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment
Year: 2013
Anemia in patients with chronic obstructive pulmonary disease - Association with comorbidities
Source: International Congress 2016 – Hospitalisation and comorbidities in chronic lung diseases
Year: 2016
Relevance of hemoglobin A1c and acute exacerbations of chronic obstructive pulmonary disease
Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations
Year: 2013
Pulmonary hypertension in patients with COPD
Source: Eur Respir Mon 2012; 57: 138-147
Year: 2012
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept